Integra Lifesciences (NSDQ:IART) today posted fourth-quarter results that beat the overall consensus on Wall Street.
The Princeton, N.J.-based surgical and medical instrument company reported profits of $45.4 billion, or 53¢ per share, on sales of $405.5 million for the three months ended Dec. 31, 2021, for a sales growth of 4.34% compared with Q4 2020.
Adjusted to exclude one-time items, earnings per share were 84¢, 1¢ ahead of The Street, where analysts were looking for sales of $403.4 million.
“Our 2021 financial performance and business achievements are a testament to our broad and differentiated product portfolio, and the resilience and commitment of our team members around the world, despite the ongoing effects of the global pandemic,” president and CEO Jan De Witte said in a news release. “I look forward to working with my Integra colleagues to continue to execute our growth priorities and accelerate our product pipeline and global opportunities in 2022 and the years to come.”
Integra Lifesciences said it expects reported revenues in Q1 to be in the range of $357 million to $365 million and an adjusted earnings per diluted share range of 67¢ to 71¢. The company notes that the revenue and earnings per share reflect the ongoing uncertainty surrounding the COVID-19 pandemic and its related impacts on business.
Shares in IART were down -2.10% to $64.01 apiece at market open.